| | ||||||||||
| 1 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| DESOGESTREL (has an active metabolite)
| DESOGESTREL |
GENITO | ORAL | F 84 PERCENT | PROGESTERONE RECEPTOR | PROGESTERONE RECEPTOR AGONIST CHEMBL208 PROGESTERONE RECEPTOR P06401 PROGESTERONE RECEPTOR HOMO SAPIENS TRANSCRIPTION FACTOR NUCLEAR RECEPTOR NR3 NR3C NR3C3 | EMA | |||
| 2 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| ETONOGESTREL (is an active metabolite)
| ETONOGESTREL | GENITO | VAGINAL IMPLANTATION | Cmax 4.8 NANOMOLAR Tmax 200 HOUR F 100 PERCENT VD 201 LITER PPB 66 PERCENT Cl 3.4 LITER / HOUR HT 29.3 HOUR | PROGESTERONE RECEPTOR | PROGESTERONE RECEPTOR AGONIST CHEMBL208 PROGESTERONE RECEPTOR P06401 PROGESTERONE RECEPTOR HOMO SAPIENS TRANSCRIPTION FACTOR NUCLEAR RECEPTOR NR3 NR3C NR3C3 | EMA | |||
